Terms: = Head and neck cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Treatment
161 results:
1. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
2. Evolutionary dynamics of tipifarnib in hras mutated head and neck squamous cell carcinoma.
Jagadeeshan S; Suryamohan K; Shin N; Mathukkada S; Boyko A; Melikhova D; Tsareva A; Yunusova L; Pravdivtseva E; Stupichev D; Shaposhnikov K; Peterson A; Bednyagin L; Shugaev-Mendosa E; Kessler L; Burrows F; Ho AL; Agrawal N; Pearson AT; Izumchenko E; Cole G; Elkabets M; Rosenberg AJ
Oral Oncol; 2024 Feb; 149():106688. PubMed ID: 38219706
[TBL] [Abstract] [Full Text] [Related]
3. Fine-needle biopsy of thyroid nodules and the contribution of molecular analysis of BRAF and RAS mutations.
Kasko M; Grigerova M; Alemayehu A; Zavodna K; Kasko V; Podoba J
Bratisl Lek Listy; 2023; 124(12):869-872. PubMed ID: 37983279
[TBL] [Abstract] [Full Text] [Related]
4. Whole exome sequencing uncovers hras mutations as potential mediators of resistance to metronomic chemotherapy.
Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
[TBL] [Abstract] [Full Text] [Related]
5. Macrofollicular Architecture in Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Pitfall in Thyroid Practice.
Yadav S; Kandasamy D; Damle N; Goel R; Chumber S; Sharma MC; Boruah M; Agarwal S
Head Neck Pathol; 2023 Dec; 17(4):899-909. PubMed ID: 37775618
[TBL] [Abstract] [Full Text] [Related]
6. Mutant hras Signaling and Rationale for Use of Farnesyltransferase Inhibitors in head and neck Squamous Cell Carcinoma.
Wang J; Al-Majid D; Brenner JC; Smith JD
Target Oncol; 2023 Sep; 18(5):643-655. PubMed ID: 37665491
[TBL] [Abstract] [Full Text] [Related]
7. Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and hras-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Smith AE; Chan S; Wang Z; McCloskey A; Reilly Q; Wang JZ; Patel HV; Koshizuka K; Soifer HS; Kessler L; Dayoub A; Villaflor V; Adkins DR; Bruce JY; Ho AL; Perez CA; Hanna GJ; Gascó Hernández A; Saunders A; Dale S; Gutkind JS; Burrows F; Malik S
Cancer Res; 2023 Oct; 83(19):3252-3263. PubMed ID: 37339176
[TBL] [Abstract] [Full Text] [Related]
8.
Alamri AM; Alkhilaiwi FA; Khan NU; Tasleem M
Anticancer Agents Med Chem; 2023; 23(19):2111-2126. PubMed ID: 37287303
[TBL] [Abstract] [Full Text] [Related]
9. Identification of crucial genes involved in thyroid cancer development.
Kalarani IB; Sivamani G; Veerabathiran R
J Egypt Natl Canc Inst; 2023 May; 35(1):15. PubMed ID: 37211566
[TBL] [Abstract] [Full Text] [Related]
10. Tumor-Infiltrating Immune Cell Landscapes in the Lymph Node Metastasis of Papillary Thyroid cancer.
Amanullah M; Pan M; Lu K; Pan X; Lu Y; Luo D; Liu P
Curr Oncol; 2023 Feb; 30(3):2625-2641. PubMed ID: 36975413
[TBL] [Abstract] [Full Text] [Related]
11. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?
Ben Yahia H; Petit FM; Saada-Bouzid E
Curr Opin Oncol; 2023 May; 35(3):178-185. PubMed ID: 36966498
[TBL] [Abstract] [Full Text] [Related]
12. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
[TBL] [Abstract] [Full Text] [Related]
13. Mutated hras Activates YAP1-AXL Signaling to Drive Metastasis of head and neck cancer.
Jagadeeshan S; Prasad M; Badarni M; Ben-Lulu T; Liju VB; Mathukkada S; Saunders C; Shnerb AB; Zorea J; Yegodayev KM; Wainer M; Vtorov L; Allon I; Cohen O; Gausdal G; Friedmann-Morvinski D; Cheong SC; Ho AL; Rosenberg AJ; Kessler L; Burrows F; Kong D; Grandis JR; Gutkind JS; Elkabets M
Cancer Res; 2023 Apr; 83(7):1031-1047. PubMed ID: 36753744
[TBL] [Abstract] [Full Text] [Related]
14.
Coleman N; Marcelo KL; Hopkins JF; Khan NI; Du R; Hong L; Park E; Balsara B; Leoni M; Pickering C; Myers J; Heymach J; Albacker LA; Hong D; Gillison M; Le X
JCO Precis Oncol; 2023 Jan; 7():e2200211. PubMed ID: 36603172
[TBL] [Abstract] [Full Text] [Related]
15. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
[TBL] [Abstract] [Full Text] [Related]
16. Unraveling molecular mechanisms of head and neck cancer.
Antra ; Parashar P; Hungyo H; Jain A; Ahmad S; Tandon V
Crit Rev Oncol Hematol; 2022 Oct; 178():103778. PubMed ID: 35932993
[TBL] [Abstract] [Full Text] [Related]
17. Clinicopathological and Molecular Features of Secondary cancer (Metastasis) to the Thyroid and Advances in Management.
Nguyen M; He G; Lam AK
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328664
[TBL] [Abstract] [Full Text] [Related]
18. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of hras Mutant head and neck Squamous Cell Carcinoma.
Javaid S; Schaefer A; Goodwin CM; Nguyen VV; Massey FL; Pierobon M; Gambrell-Sanders D; Waters AM; Lambert KN; Diehl JN; Hobbs GA; Wood KC; Petricoin EF; Der CJ; Cox AD
Mol Cancer Ther; 2022 May; 21(5):762-774. PubMed ID: 35247914
[TBL] [Abstract] [Full Text] [Related]
19. k-ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications.
Nakahata K; Simons BW; Pozzo E; Shuck R; Kurenbekova L; Prudowsky Z; Dholakia K; Coarfa C; Patel TD; Donehower LA; Yustein JT
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35174853
[TBL] [Abstract] [Full Text] [Related]
20. Genomic Alterations in head and neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
Marret G; Bièche I; Dupain C; Borcoman E; du Rusquec P; Ricci F; Hescot S; Sablin MP; Tresca P; Bello D; Dubot C; Loirat D; Frelaut M; Lecerf C; Le Tourneau C; Kamal M
JCO Precis Oncol; 2021 Nov; 5():215-226. PubMed ID: 34994597
[TBL] [Abstract] [Full Text] [Related]
[Next]
